Market Flux
Open the Terminal

Top Mover

Regeneron Surges Nearly 14% After Q3 Revenue and EPS Smash Estimates on Dupixent and EYLEA HD Strength

By Market Flux··1 min read
Read this in the Market Flux app

Regeneron Pharmaceuticals, Inc. $REGN

$927.37+13.42%as of publication

5D Change
+15.18%
Market Cap
$84.30B

Regeneron Pharmaceuticals posted a blowout third quarter on October 30, 2026, with revenue of $5.12 billion beating the Wall Street consensus of roughly $4.54 billion by more than $540 million and rising 36% year over year. Adjusted EPS of $20.07 surged 70% year over year and topped estimates of around $16.24 by nearly $4, prompting a sharp rally that made REGN the top gainer in both the S&P 500 and Nasdaq 100 for the session, with shares climbing roughly 13.9% and touching a 52-week high of $869.43.

The quarter was powered by record net sales across three key franchises. Global Dupixent net sales, recorded by partner Sanofi, rose 35% year over year to $6.5 billion. EYLEA HD U.S. net sales jumped 62% to $699 million as the higher-dose formulation continued to take share, while legacy EYLEA U.S. sales declined 41% to $400 million reflecting that market transition. Libtayo global net sales climbed 51% to $550 million, and Sanofi collaboration revenue surged 68% to $2.72 billion.

Regenerons management called it

© AI-generated summary is provided by Market Flux

Sources

  1. BenzingaTop Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings
  2. MarketWatchRegeneron Pharma 3Q Sales Climb on Dupixent Growth
  3. WallstengineToday's Key Events (All EST) — 10/30/2026 09:45: US Chicago PMI 12:00: Fed's Daly 12:30: Fed's Musalem 13:00: US Baker Hughes Total Rig Count Before Open 👇 ExxonMobil (XOM) AbbVie (ABBV) Chevron (CVX) AstraZeneca (AZN) BP (BP) Sanofi (SNY) General Dynamics (GD) Regeneron Pharmaceuticals (REGN)
  4. Yahoo FinanceWhat Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
  5. Seeking AlphaRegeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M
  6. LiveSquawk$REGN | Regeneron Q3 2026 Earnings - Adj EPS: $4.23 (est $4.13) - Rev: $5.1B (est $4.57B)
  7. NasdaqRegeneron Pharmaceuticals Inc Reports Increase In Q3 Income
  8. BioStocks$REGN Q3 EPS $20.07 beats $16.19 Est Sales $5.1B beat $4.5B Est EYLEA HD U.S. net sales increased 62% to $699M EYLEA U.S. net sales decreased 41% to $400M
Show 5 more
  1. OpenOutcrier$REGN (+6.9% pre) Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
  2. BPharmCatalyst$ABOS reported Phase 2 ALTITUDE-AD data for sabirnetug in 542 early Alzheimer's patients. The trial missed primary iADRS and key secondary endpoints (including CDR-SB) at 18 months despite plaque clearance, with ARIA-E in 10% of subjects. Acumen is halting development, reducing costs, and exploring strategic options. $CDNA $ABOS $OABI $REGN $NRXP $ATEC $INTS $PBM $PMN $TARA See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
  3. Marketsday#Pre-Market Buzz, October 30, 2026 🔹 Capri Holdings $CPRI experiences pre-market trading activity amidst broader retail sector movements. 🔹 Mondelez International $MDLZ topped Q3 profit estimates with an adjusted EPS of $0.78 on revenue of $9.97B. 🔹 Regeneron Pharmaceuticals $REGN beat Q3 FY26 estimates, posting EPS of $20.07 on revenue of $5.12B, up 36% YoY. 🔹 Rivian Automotive $RIVN trades actively ahead of the bell as EV sector sentiment recalibrates. 🔹 Gilead Sciences $GILD sees pre-market interest following recent pipeline and financial updates. 🔹 General Dynamics $GD remains in focus across aerospace and defense counters. 🔹 Rocket Companies $RKT tracks mortgage rate trends and housing finance expectations.
  4. TheflynewsMorning Movers: Intel continues to plummet after earnings $ABBV $OMF $GD $OIS $SNY $AZN $REGN $FMC $LYB $NWL $RDDT $INTC $AMZN $RBLX $COIN $HOOD $MSTR $CRCL $XOM
  5. 24/7 Wall StreetRegeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up